The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.本揭示係關於新穎種類之抗HER2單株抗體，其包括在每一Fc上具有相同N-聚醣之抗HER2 IgG分子之均質群體。本發明抗體可自抗HER2單株抗體由Fc醣改造產生。重要的是與未經醣改造之相應單株抗體相比，本發明抗體具有改良之治療價值與增加之ADCC活性及增加之Fc受體結合親和力。
